Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Phase 1

Terminated

Conditions: Osteogenesis Imperfecta

Interventions: Drug: SAR439459
Drug: Placebo

First Posted Date: 2022-02-09

Last Posted Date: 2024-11-28

Lead Sponsor: Sanofi

Target Recruit Count: 16

Registration Number: NCT05231668

Locations: 🇺🇸
UCLA Health_Site Number: 8400006, Los Angeles, California, United States
🇺🇸
Yale University - Site Number:8400007, New Haven, Connecticut, United States
🇺🇸
Indiana University School of Medicine_Site Number: 8400002, Indianapolis, Indiana, United States

and more 10 locations

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

Phase 3

Active, not recruiting

Conditions: Gaucher's Disease Type III

Interventions: Drug: Venglustat
Drug: imiglucerase

First Posted Date: 2022-02-03

Last Posted Date: 2025-01-13

Lead Sponsor: Sanofi

Target Recruit Count: 43

Registration Number: NCT05222906

Locations: 🇺🇸
Yale University School of Medicine - Investigational Site Number: 8400003, New Haven, Connecticut, United States
🇺🇸
University of Iowa - Investigational Site Number: 8400002, Iowa City, Iowa, United States
🇺🇸
Texas Oncology - Medical City Dallas Site Number : 8400008, Dallas, Texas, United States

and more 19 locations

A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries

Completed

Conditions: Dermatitis Atopic

First Posted Date: 2022-01-28

Last Posted Date: 2023-11-29

Lead Sponsor: Sanofi

Target Recruit Count: 187

Registration Number: NCT05214326

Locations: 🇰🇼
Investigational site Kuwait, Kuwait, Kuwait
🇸🇦
Investigational site Saudi Arabia, Saudi Arabia, Saudi Arabia
🇦🇪
Investigational site United Arab Emirates, United Arab Emirates, United Arab Emirates

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Phase 3

Active, not recruiting

Conditions: Fabry Disease

Interventions: Drug: Venglustat (GZ402671)
Drug: Placebo

First Posted Date: 2022-01-25

Last Posted Date: 2025-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 122

Registration Number: NCT05206773

Locations: 🇺🇸
Nephrology Clinic at Kirklin Clinic of UAB Hospital_Investigational Site Number: 8400011, Birmingham, Alabama, United States
🇺🇸
UCLA Medical Center_Investigational Site Number: 8400006, Los Angeles, California, United States
🇺🇸
University of California Irvine Medical Center- Site Number : 8400019, Orange, California, United States

and more 55 locations

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Phase 2

Active, not recruiting

Conditions: Classic Hodgkin Lymphoma
Diffuse Large B-cell Lymphoma

Interventions: Drug: THOR-707
Drug: Pembrolizumab

First Posted Date: 2022-01-05

Last Posted Date: 2024-03-28

Lead Sponsor: Sanofi

Target Recruit Count: 14

Registration Number: NCT05179603

Locations: 🇨🇱
Investigational Site Number : 1520002, Santiago, Reg Metropolitana De Santiago, Chile
🇨🇱
Investigational Site Number : 1520004, Vina del Mar, Valparaíso, Chile
🇨🇱
Investigational Site Number : 1520001, Temuco, Chile

and more 5 locations

Resection Observatory

Completed

Conditions: Metastatic Colorectal Cancer
Colorectal Neoplasms

Interventions: Drug: Fluorouracil
Drug: Aflibercept
Drug: Irinotecan

First Posted Date: 2022-01-05

Last Posted Date: 2025-01-30

Lead Sponsor: Sanofi

Target Recruit Count: 140

Registration Number: NCT05178745

BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)

Phase 2

Active, not recruiting

Conditions: Transplant Rejection

Interventions: Drug: BIVV020 (SAR445088)
Drug: Antithymocyte globulin (ATG)
Drug: Intravenous immunoglobulin (IVIg)
Drug: Rituximab or biosimilar
Drug: Corticosteroids
Drug: Tacrolimus
Drug: Mycophenolate

First Posted Date: 2021-12-14

Last Posted Date: 2025-01-10

Lead Sponsor: Sanofi

Target Recruit Count: 48

Registration Number: NCT05156710

Locations: 🇺🇸
Massachusetts General Hospital- Site Number : 8400007, Boston, Massachusetts, United States
🇺🇸
Cedars-Sinai Medical Center- Site Number : 8400100, Los Angeles, California, United States
🇺🇸
University of California Los Angeles Medical Center- Site Number : 8400103, Los Angeles, California, United States

and more 24 locations

Efficacy and Safety of FIRTECH in Patients With Mild to Moderate Acute Low Back Pain

Phase 3

Completed

Conditions: Low Back Pain

Interventions: Device: ITP FIRTECH

First Posted Date: 2021-11-30

Last Posted Date: 2022-12-16

Lead Sponsor: Sanofi

Target Recruit Count: 221

Registration Number: NCT05137041

Locations: 🇮🇹
Investigational Site Number :5, Alessandria, Italy
🇩🇪
Investigational Site Number :01, Munich, Germany
🇮🇹
Investigational Site Number :7, Taormina, Messina, Italy

and more 4 locations

Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

Phase 3

Completed

Conditions: Cold Agglutinin Disease

Interventions: Drug: sutimlimab

First Posted Date: 2021-11-24

Last Posted Date: 2023-10-03

Lead Sponsor: Sanofi

Target Recruit Count: 7

Registration Number: NCT05132127

Locations: 🇯🇵
Investigational Site Number 3920003, Osaka, Japan
🇯🇵
Investigational Site Number 3920002, Saitama, Japan
🇯🇵
Investigational Site Number 3920001, Tokyo, Japan

and more 2 locations

Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis

Phase 3

Terminated

Conditions: Myasthenia Gravis

Interventions: Drug: Tolebrutininb
Drug: Placebo

First Posted Date: 2021-11-24

Last Posted Date: 2024-04-08

Lead Sponsor: Sanofi

Target Recruit Count: 6

Registration Number: NCT05132569

Locations: 🇨🇳
Investigational Site Number :1560003, Chengdu, China
🇨🇳
Investigational Site Number :1560001, Shanghai, China
🇨🇳
Investigational Site Number :1560002, Wuhan, China

and more 19 locations

Home Terms & Conditions Privacy Policy